InterAx Biotech's AI platform unlocks new drug designs for diabetes, obesity, and cancer

14.02.2024 15:47, Rita Longobardi

InterAx Biotech, a leader in computational pharmacology, announces its AI platform has identified novel drug targets, laying the ground for potential oral treatments for diabetes, obesity, and even cancer. Particularly promising results are coming from the development of a potential oral alternative to Tirzepatide (Mounjaro) for metabolic disorders and weight loss.

The InterAx approach, together with the latest results on the immune-oncology program, will be presented at the upcoming GPCRs-Targeted Drug Discovery Summit. The company's success story includes an innovative small molecule identified for aggressive cancers, which triggers a potent anti-tumor immune response through a novel mechanism. This opens doors for broader applicability of immunotherapies and faster regulatory pathways. 

Additionally, InterAx's metabolic programs are following a similar successful development path, aiming for potential breakthroughs in treating diabetes and obesity.

InterAx was ranked among the TOP 100 Swiss Startups from 2017 to 2019, participated in Venture Leaders China in 2018 and Venture Leaders Life Sciences in 2016, and won the last stage of Venture Kick in 2016.

"The most interesting part of the Venture Leaders China program for me was the opportunity to understand Chinese Pharma companies' needs and strategies. This was very useful for setting up the InterAx Biotech development plan in China," stated Aurélien Rizk, CSO of InterAx Biotech.


InterAx Biotech's team